TrivarX Limited (MDBIF)
OTHER OTC:MDBIF
Want to see MDBIF full AI Analyst Report?
MDBIF Stock Chart & Stats
$0.02
>-$0.01(-69.43%)
At close: 4:00 PM EST
$0.02
>-$0.01(-69.43%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume875.00
Average Volume (3M)0.00
Market Cap
$18.17M
Enterprise Value$24.30M
Total Cash (Recent Filing)$1.25M
Total Debt (Recent Filing)$169.03K
Price to Earnings (P/E)―
Beta-1.21
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-463.22
Enterprise Value/Ebitda-12.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeverageVery low debt-to-equity (~0.013) and a ~12.65M equity base provide a durable capital cushion for a small medical-info business. This reduces near-term refinancing risk, supports R&D or commercialization runway, and gives management flexibility over the next several months.
Material Improvement In Free Cash FlowFree cash flow improved sharply from -3.70M to -0.19M year-over-year, indicating the company materially reduced cash burn. This trend improves runway without immediate external funding and reflects durable operational progress rather than a one-off timing effect.
Reduction In Net Losses Year-over-yearNet loss narrowed from -1.24M to -0.94M, signaling persistent but improving cost control or operational traction. A sustained reduction in losses, if continued, reduces cumulative deficit growth and lowers the frequency/size of future financing needs over a 2-6 month horizon.
Bears Say
Zero Reported RevenueReported revenue of zero in FY2024 and FY2025 prevents assessment of product-market fit and operating scalability. Without recurring revenue, margins, pricing power, and unit economics remain unproven, limiting sustainable growth prospects over the medium term.
Sustained Negative Operating And Free Cash FlowContinued negative operating and free cash flow means the business is not self-sustaining and will likely need external capital to fund operations or growth. Reliance on financing increases execution risk and dilutive outcomes, a structural constraint for the next several quarters.
Negative Operating Profitability And Returns On EquityNegative EBITDA/EBIT plus a ~-7.5% ROE indicate core operations and capital are destroying value. Persistent negative operating profitability undermines long-term sustainability, forces strategic tradeoffs, and increases dependency on non-operating funding over multiple quarters.
TrivarX Limited News
MDBIF FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is $18.17M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 114 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in MDBIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---